JP2022527709A5 - - Google Patents
Info
- Publication number
- JP2022527709A5 JP2022527709A5 JP2021557392A JP2021557392A JP2022527709A5 JP 2022527709 A5 JP2022527709 A5 JP 2022527709A5 JP 2021557392 A JP2021557392 A JP 2021557392A JP 2021557392 A JP2021557392 A JP 2021557392A JP 2022527709 A5 JP2022527709 A5 JP 2022527709A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- plasmid
- transgene
- aav
- crispr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025106768A JP2025160172A (ja) | 2019-03-27 | 2025-06-24 | Ｃａｓ９／ｒｎｐおよびａａｖウイルスの組み合わせを使用したがん免疫療法のための、キメラ抗原受容体（ｃａｒ）－初代ｎｋ細胞の生成 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825007P | 2019-03-27 | 2019-03-27 | |
| US62/825,007 | 2019-03-27 | ||
| PCT/US2020/025454 WO2020198675A1 (en) | 2019-03-27 | 2020-03-27 | Generation of chimeric antigen receptor (car)-primary nk cells for cancer immunotherapy using a combination of cas9/rnp and aav viruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106768A Division JP2025160172A (ja) | 2019-03-27 | 2025-06-24 | Ｃａｓ９／ｒｎｐおよびａａｖウイルスの組み合わせを使用したがん免疫療法のための、キメラ抗原受容体（ｃａｒ）－初代ｎｋ細胞の生成 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527709A JP2022527709A (ja) | 2022-06-03 |
| JP2022527709A5 true JP2022527709A5 (https=) | 2023-03-31 |
| JP7702878B2 JP7702878B2 (ja) | 2025-07-04 |
Family
ID=72611833
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557392A Active JP7702878B2 (ja) | 2019-03-27 | 2020-03-27 | Ｃａｓ９／ｒｎｐおよびａａｖウイルスの組み合わせを使用したがん免疫療法のための、キメラ抗原受容体（ｃａｒ）－初代ｎｋ細胞の生成 |
| JP2025106768A Pending JP2025160172A (ja) | 2019-03-27 | 2025-06-24 | Ｃａｓ９／ｒｎｐおよびａａｖウイルスの組み合わせを使用したがん免疫療法のための、キメラ抗原受容体（ｃａｒ）－初代ｎｋ細胞の生成 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106768A Pending JP2025160172A (ja) | 2019-03-27 | 2025-06-24 | Ｃａｓ９／ｒｎｐおよびａａｖウイルスの組み合わせを使用したがん免疫療法のための、キメラ抗原受容体（ｃａｒ）－初代ｎｋ細胞の生成 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220177917A1 (https=) |
| EP (1) | EP3946432A4 (https=) |
| JP (2) | JP7702878B2 (https=) |
| KR (1) | KR20220017887A (https=) |
| CN (1) | CN113891727A (https=) |
| AU (1) | AU2020248097A1 (https=) |
| BR (1) | BR112021019180A2 (https=) |
| CA (1) | CA3135198A1 (https=) |
| CO (1) | CO2021014353A2 (https=) |
| IL (1) | IL286701A (https=) |
| MX (1) | MX2021011782A (https=) |
| PH (1) | PH12021552383A1 (https=) |
| SG (1) | SG11202110613SA (https=) |
| WO (1) | WO2020198675A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12473336B2 (en) | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| MX2023004811A (es) * | 2020-10-26 | 2023-06-29 | Res Institute At Nationwide Children´S Hospital | Células nk del receptor de antígeno quimérico (car) y usos de las mismas. |
| WO2022236174A1 (en) * | 2021-05-07 | 2022-11-10 | Washington University | In situ car-t therapies, vectors and methods therefor |
| US20240254445A1 (en) * | 2021-06-01 | 2024-08-01 | Vaxcell-Bio | Composition containing feeder cell for proliferating natural killer cell |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3196301B1 (en) * | 2012-07-11 | 2018-10-17 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of monogenic diseases |
| JP7103750B2 (ja) * | 2013-12-12 | 2022-07-20 | ザ・ブロード・インスティテュート・インコーポレイテッド | ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用 |
| SG10201913782UA (en) * | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| AU2015330699B2 (en) * | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| BR112017024514A2 (pt) * | 2015-05-16 | 2018-07-24 | Genzyme Corporation | edição genética de mutações intrônicas profundas |
| CN108026526B (zh) * | 2015-06-09 | 2023-05-12 | 爱迪塔斯医药公司 | 用于改善移植的crispr/cas相关方法和组合物 |
| CN109715801B (zh) * | 2015-12-01 | 2022-11-01 | 克里斯普治疗股份公司 | 用于治疗α1抗胰蛋白酶缺乏的材料和方法 |
| AU2017347854B2 (en) | 2016-10-27 | 2022-12-08 | Intima Bioscience, Inc. | Viral methods of T cell therapy |
| US11655275B2 (en) * | 2017-05-03 | 2023-05-23 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene |
| EP3645038B1 (en) * | 2017-06-30 | 2026-02-18 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
-
2020
- 2020-03-27 SG SG11202110613SA patent/SG11202110613SA/en unknown
- 2020-03-27 WO PCT/US2020/025454 patent/WO2020198675A1/en not_active Ceased
- 2020-03-27 BR BR112021019180A patent/BR112021019180A2/pt unknown
- 2020-03-27 CA CA3135198A patent/CA3135198A1/en active Pending
- 2020-03-27 EP EP20777892.9A patent/EP3946432A4/en active Pending
- 2020-03-27 PH PH1/2021/552383A patent/PH12021552383A1/en unknown
- 2020-03-27 US US17/598,619 patent/US20220177917A1/en active Pending
- 2020-03-27 KR KR1020217034800A patent/KR20220017887A/ko active Pending
- 2020-03-27 JP JP2021557392A patent/JP7702878B2/ja active Active
- 2020-03-27 MX MX2021011782A patent/MX2021011782A/es unknown
- 2020-03-27 AU AU2020248097A patent/AU2020248097A1/en active Pending
- 2020-03-27 CN CN202080036500.4A patent/CN113891727A/zh active Pending
-
2021
- 2021-09-26 IL IL286701A patent/IL286701A/en unknown
- 2021-10-26 CO CONC2021/0014353A patent/CO2021014353A2/es unknown
-
2025
- 2025-06-24 JP JP2025106768A patent/JP2025160172A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220135970A1 (en) | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa | |
| JP2022527709A5 (https=) | ||
| Ehrke-Schulz et al. | CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes | |
| US12460231B2 (en) | Crispr/CAS-related methods and compositions for treating primary open angle glaucoma | |
| EP3353296B1 (en) | Use of exonucleases to improve crispr/cas-mediated genome editing | |
| CN109153994A (zh) | 用于治疗β-血红蛋白病的CRISPR/CAS相关方法和组合物 | |
| JP2020524998A5 (https=) | ||
| WO2017075475A1 (en) | Crispr/cas-related methods and compositions for treating herpes simplex virus | |
| CN104805118A (zh) | 一种苏禽黄鸡胚胎干细胞特定基因进行靶向敲除方法 | |
| CN111218447A (zh) | 使用统治型gRNA的CRISPR相关方法和组合物 | |
| JP2023552917A5 (https=) | ||
| CN113226336B (zh) | 一种在细胞中递送基因的方法 | |
| WO2021243058A1 (en) | Biallelic knockout of sarm1 | |
| Davis et al. | CRISPR advancements for human health | |
| Yin et al. | Recent advances in CRISPR-Cas system for the treatment of genetic hearing loss | |
| JP2025502346A (ja) | Ｖｅｇｆを調節する方法およびその使用 | |
| CN109628493B (zh) | 一种用于制备可异体移植t细胞的基因编辑系统 | |
| WO2025128722A2 (en) | Methods and compositions for genomic integration | |
| KR20240087635A (ko) | B형 간염 바이러스(hbv) 녹아웃 | |
| JP2024542882A (ja) | 細胞治療において使用するｓａｒｍ１の発現の減少 | |
| RU2021131306A (ru) | Получение первичных nk-клеток с химерными антигенными рецепторами (car) для иммунотерапии онкологических заболеваний с использованием комбинации cas9/рнп и вирусов aav | |
| WO2020253753A1 (zh) | 一种内含子异常剪接的修复方法、产品和应用 | |
| HK40094039A (zh) | Sarm1的双等位基因敲除 | |
| WO2024191731A1 (en) | Compositions, systems, and methods for treating familial hypercholesterolemia by targeting pcsk9, ldlr, and/or angptl3 | |
| CN120290534A (zh) | 腺嘌呤脱氨酶、包含其的碱基编辑器融合蛋白和碱基编辑器系统及其应用 |